iScience (Jan 2023)
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
- Daryl Geers,
- Roos S.G. Sablerolles,
- Debbie van Baarle,
- Neeltje A. Kootstra,
- Wim J.R. Rietdijk,
- Katharina S. Schmitz,
- Lennert Gommers,
- Susanne Bogers,
- Nella J. Nieuwkoop,
- Laura L.A. van Dijk,
- Eva van Haren,
- Melvin Lafeber,
- Virgil A.S.H. Dalm,
- Abraham Goorhuis,
- Douwe F. Postma,
- Leo G. Visser,
- Anke L.W. Huckriede,
- Alessandro Sette,
- Alba Grifoni,
- Rik L. de Swart,
- Marion P.G. Koopmans,
- P. Hugo M. van der Kuy,
- Corine H. GeurtsvanKessel,
- Rory D. de Vries
Affiliations
- Daryl Geers
- Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands
- Roos S.G. Sablerolles
- Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands
- Debbie van Baarle
- Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands
- Neeltje A. Kootstra
- Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Infection and Immunity Institute, University of Amsterdam, Amsterdam, the Netherlands
- Wim J.R. Rietdijk
- Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands
- Katharina S. Schmitz
- Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands
- Lennert Gommers
- Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands
- Susanne Bogers
- Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands
- Nella J. Nieuwkoop
- Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands
- Laura L.A. van Dijk
- Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands
- Eva van Haren
- Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands
- Melvin Lafeber
- Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
- Virgil A.S.H. Dalm
- Department of Internal Medicine, Division of Allergy & Clinical Immunology and Department of Immunology, Erasmus Medical Center, Rotterdam, the Netherlands
- Abraham Goorhuis
- Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam, the Netherlands; Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the Netherlands
- Douwe F. Postma
- Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, Groningen, the Netherlands
- Leo G. Visser
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands
- Anke L.W. Huckriede
- Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- Alessandro Sette
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, La Jolla, CA, USA
- Alba Grifoni
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA
- Rik L. de Swart
- Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands
- Marion P.G. Koopmans
- Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands
- P. Hugo M. van der Kuy
- Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands
- Corine H. GeurtsvanKessel
- Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands
- Rory D. de Vries
- Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands; Corresponding author
- Journal volume & issue
-
Vol. 26,
no. 1
p. 105753
Abstract
Summary: The emergence of novel SARS-CoV-2 variants led to the recommendation of booster vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster vaccination induces high antibody levels, but how heterologous boosters affect other functional aspects of the immune response remained unknown. Here, we performed immunological profiling of Ad26.COV2.S-primed individuals before and after homologous or heterologous (mRNA-1273 or BNT162b2) booster. Booster vaccinations increased functional antibodies targeting ancestral SARS-CoV-2 and emerging variants. Especially heterologous booster vaccinations induced high levels of functional antibodies. In contrast, T-cell responses were similar in magnitude following homologous or heterologous booster vaccination and retained cross-reactivity towards variants. Booster vaccination led to a minimal expansion of SARS-CoV-2-specific T-cell clones and no increase in the breadth of the T-cell repertoire. In conclusion, we show that Ad26.COV2.S priming vaccination provided a solid immunological base for heterologous boosting, increasing humoral and cellular responses targeting emerging variants of concern.
